Halla Nimeiri MD

Oncology•Chicago, IL

Associate Professor in Medicine-Hematology/Oncology, Northwestern University Feinberg Medical School

Join to View Full Profile

251 E Huron StChicago, IL 60611
Phone+1 312-926-2000
Fax+1 312-926-2411

Education & Training

University of ChicagoFellowship, Hematology and Medical Oncology, 2005 - 2008
Mercy Catholic Medical CenterResidency, Internal Medicine, 2002 - 2005
University of Khartoum Faculty of MedicineClass of 1992

Certifications & Licensure

IL State Medical License 2005 - 2026
PA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2011

Clinical Trials

Vitamin D Supplement in Preventing Colon Cancer in African Americans With Colon Polyps Start of enrollment: 2009 Feb 01
Terminated
Not Applicable
Chemoembolization Versus Radioembolization in Treating Patients With Liver Cancer That Cannot Be Treated With Radiofrequency Ablation Or Surgery Start of enrollment: 2009 Aug 01
Completed
Phase 2
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2009 Nov 17
Completed
Phase 1
E7050 in Combination With Cisplatin and Capecitabine Versus Cisplatin and Capecitabine Alone in Patients With Advanced or Metastatic Solid Tumors and Previously Untreated Gastric Cancer Start of enrollment: 2011 Nov 01
Terminated
Phase 1, Phase 2
Temozolomide and Pazopanib Hydrochloride in Treating Patients With Advanced Pancreatic Neuroendocrine Tumors That Cannot Be Removed By Surgery Start of enrollment: 2011 Dec 12
Completed
Phase 1, Phase 2
Study of Vitamin D in Untreated Metastatic Colorectal Cancer Start of enrollment: 2012 Apr 13
Completed
Phase 2
Phase II Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma Start of enrollment: 2012 Oct 05
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Real-World Validation of the Purity Independent Subtyping of Tumors Classifier for Informing Therapy Selection in Pancreatic Ductal Adenocarcinoma.
Stephane Wenric, Chithra Sangli, John Guittar, Farahnaz Islam, Alia Zander
JCO Precision Oncology. 2025-09-01
Outcomes Following First-Line Immune Checkpoint Inhibitors With or Without Chemotherapy Stratified by KRAS Mutational Status-A Real-World Analysis in Patients With Adv...
David J Cantor, Halla Nimeiri, Leora Horn, Matthew West, Rotem Ben-Shachar
Clinical Lung Cancer. 2025-09-01
Real-World Adherence Patterns of Comprehensive Genomic Profiling to Biomarker Recommended Therapies in Patients With Advanced Non-Small Cell Lung Cancer.
Rotem Ben-Shachar, Kaveri Nadhamuni, Luis E Raez, Mark Carty, Akash Mitra
JCO Oncology Practice. 2025-06-30

Press Mentions

Tempus Introduces xM, an Assay to Monitor Immunotherapy Response for Patients with Advanced CancersJune 2nd, 2025
Tempus Publishes Study Highlighting Benefits of Concurrent RNA and DNA Sequencing in Advanced Cancer CareNovember 11th, 2024
Tempus Expands Immuno-Oncology Portfolio with Launch of AI-Enabled, Multimodal Immune Profile Algorithmic TestsJuly 16th, 2024